A 58-year-old man with a 10-year history of hypertension and diabetes mellitus type 2 presents with progressive dyspnea on exertion and orthopnea for the past 3 months. On examination, he has a blood pressure of 138/88 mmHg, heart rate 92/min, elevated JVP, bilateral ankle edema, and a displaced apex beat. Chest X-ray shows pulmonary edema. Echocardiography reveals an ejection fraction of 32% with global hypokinesis. He is started on lisinopril and furosemide. After 2 weeks, his symptoms improve but he develops a persistent dry cough. What is the most appropriate next step in his pharmacological management?

Explanation

## Clinical Context This patient has symptomatic heart failure with reduced ejection fraction (HFrEF, EF 32%) and has developed an ACE inhibitor–induced cough, a well-known adverse effect affecting 10–20% of patients. ## Mechanism of ACE Inhibitor Cough **Key Point:** ACE inhibitors block the conversion of angiotensin I to angiotensin II, but they also prevent the degradation of bradykinin. Accumulation of bradykinin in the lungs stimulates vagal C-fibers, triggering a dry, persistent cough. This is a class effect and occurs in both ACE inhibitors and is NOT dose-dependent. ## Management Strategy **High-Yield:** When an ACE inhibitor causes intolerable cough, the standard approach is to switch to an angiotensin II receptor blocker (ARB). ARBs block the AT1 receptor downstream, preventing angiotensin II effects WITHOUT causing bradykinin accumulation. They provide equivalent cardioprotection in HFrEF. **Clinical Pearl:** The patient requires continuation of neurohormonal blockade (ACE-I or ARB) and addition of a beta-blocker (e.g., carvedilol, metoprolol succinate) — both are Class I recommendations in HFrEF guidelines. This combination forms the foundation of HFrEF therapy. ## Why Option 1 (Replace with ARB + Add Beta-Blocker) is Correct - **ARB substitution:** Avoids bradykinin accumulation while maintaining angiotensin II antagonism. - **Beta-blocker addition:** Reduces mortality and hospitalizations in HFrEF; should be initiated early (after initial diuresis and hemodynamic stabilization). - **Guideline-aligned:** Both ACE-I/ARB and beta-blockers are foundational therapy in HFrEF. ## Comparison of Neurohormonal Agents in HFrEF | Agent Class | Mechanism | Cough Risk | Hyperkalemia Risk | HFrEF Benefit | |---|---|---|---|---| | ACE inhibitor | Blocks ACE; ↓ bradykinin degradation | **High (10–20%)** | Moderate | Mortality ↓ | | ARB | Blocks AT1 receptor | **None** | Moderate | Mortality ↓ | | Beta-blocker | β1/β2 antagonism | None | None | Mortality ↓, HF hospitalizations ↓ | | Aldosterone antagonist | Blocks mineralocorticoid receptor | None | **High** | Mortality ↓ (in advanced HF) | **Mnemonic:** **ARNI** = Angiotensin Receptor Neprilysin Inhibitor (sacubitril/valsartan); **ACE-I/ARB + BB + MRA** = Triple therapy foundation for HFrEF. ## Why Other Options Are Suboptimal **Option 1 (Antihistamine):** Does not address the underlying cause; bradykinin continues to accumulate. Cough will persist. **Option 3 (Increase furosemide + spironolactone):** Addresses volume overload but does NOT solve the ACE-I intolerance. Spironolactone is appropriate in advanced HF but is not the immediate next step here. **Option 4 (Hydralazine + isosorbide dinitrate):** Older vasodilator combination used in African Americans or ACE-I/ARB-intolerant patients; less evidence than ACE-I/ARB in HFrEF. Not first-line for ACE-I cough when ARBs are available.